Printer Friendly

Novartis AG won approval for the hypertension medicine Tekturna--a potential blockbuster that has shown the ability to lower blood pressure more effectively than common treatments.

Studies have shown that Tekturna is able to keep blood pressure down for more than 24 hours. Elsewhere, Pfizer Inc. (New York) received clearance to promote the cholesterol drug Lipitor, for five new uses to help heart patients and people at risk for stroke. The drug was approved to lower the risk of nonfatal heart attacks, fatal and nonfatal strokes, certain types of heart surgery, hospitalization for heart surgery, and chest pain in patients with heart disease. Quest Diagnostics Inc. (Lyndhurst NJ) won clearance for its herpes simplex virus test. The new Plexus HerpeSelect tests both HSV type-1 and type-2. Respironics Inc. (Murrysville PA) was cleared to sell its Bipap autoSV device for people with breathing problems during sleep. The device uses software to recognize breathing abnormalities and correct them when they occur. And Teva Pharmaceutical Industries Ltd. was cleared to sell a generic version of German drugmaker Schwarz Pharma AG's Uniretic tablets for treating high blood pressure.
COPYRIGHT 2007 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:FDA ROUNDUP
Date:Mar 12, 2007
Previous Article:Biovail Corp.
Next Article:Weekly stock performance (as of September 14, 2007).

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters